A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer

July 21, 2020 updated by: Laboratoires Leurquin Mediolanum

A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy

GX301 is an experimental therapeutic vaccine directed against human telomerase, an enzyme playing an essential role in cancer cell proliferation.

This clinical trial will test three different GX301 administration regimens in castration-resistant prostate cancer patients who have achieved response or disease stability with first-line docetaxel treatment. This is aimed at identifying an optimal vaccination regimen.

The three regimens will primarily be compared for their efficacy and safety in inducing vaccine-specific immunological responses over a period of 6 months following treatment initiation. In addition, patients will be observed for the occurrence of disease progression and for their vital status up to 24 months.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

GX301, an experimental therapeutic (anti-cancer) vaccine, is composed of four immunogenic peptides from human telomerase and two complementary adjuvants, Montanide ISA-51 VG and imiquimod.

An earlier Phase 1 study of GX301 has provided evidence of vaccine-specific immune response in a small sample of stage 4 prostate cancer patients given eight GX301 administrations over 9 weeks.

The present Phase 2, randomised, parallel-group, multicentre trial is aimed at comparing three different GX301 administration regimens in patients with progressive, castration-resistant prostate cancer who have completed a first-line docetaxel treatment and have achieved response to chemotherapy or disease stability. Primary comparisons will include regimen efficacy in inducing vaccine-specific immunological responses over a period of 6 months following randomisation; and treatment safety and tolerability over the same period.

A further study aim is to investigate whether achievement of immunological response, irrespective of the assigned GX301 regimen, is related to progression-free and/or overall survival.

Eligible patients will be randomly assigned to receive one of three GX301 vaccination regimens consisting of two, four or eight administrations, respectively, each regimen being given over a fixed 9-week period. Randomisation ratio will be 1:1:1. Randomisation will be stratified by previous cumulative exposure to docetaxel.

Following randomisation, immunological responses to GX301 will be determined over a 6-month period. However, on-study patient observation will be continued until the occurrence of one of the following end-points, whichever the earliest: (a) disease progression; (b) death; (c) completion of an 18-month observation period; or (d) patient's decision to terminate his participation in the study.

All patients discharged from the trial for reasons (a) or (c) will undergo a follow-up to ascertain survival until 24 months from randomisation.

Data analysis will be carried out in two sequential steps. The first step will focus on co-primary outcomes and will therefore take place upon completion of the study dataset up to the 6-month time-point. The second step will incorporate secondary outcomes and will therefore be conducted upon completion of the full study dataset.

Study Type

Interventional

Enrollment (Actual)

99

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Alessandria, Italy, 15121
        • S.C. di Oncologia, A.S.O. "Santi Antonio e Biagio e Cesare Arrigo"
      • Aviano, Italy, 33081
        • Oncologia Medica A, Centro di Riferimento Oncologico (CRO)
      • Bari, Italy, 70124
        • Oncologia Medica, Azienda Ospedaliero Universitaria - Policlinico Consorziale
      • Bari, Italy, 70124
        • U.O.C. Urologia 1, A.O.U. Consorziale Policlinico di Bari
      • Brescia, Italy, 25123
        • Oncologia Medica, A.O. Spedali Civili
      • Busto Arsizio, Italy, 21052
        • S.C. Oncologia Medica, Presidio Ospedaliero Busto Arsizio
      • Candiolo, Italy, 10060
        • IRCCS Fondazione del Piemonte per l'Oncologia (FPO)
      • Genova, Italy, 16132
        • Clinica di Oncologia Medica, IRCCS San Martino-IST
      • Milano, Italy, 20132
        • U.O. Medicina Oncologica - Ospedale San Raffaele IRCCS
      • Milano, Italy, 20141
        • Unità Oncologica Medica Urogenitale, Istituto Europeo di Oncologia
      • Napoli, Italy, 80131
        • Dipartimento Uro-Ginecologico, IRCCS Istituto Nazionale Tumori - Fondazione Pascale
      • Napoli, Italy, 80131
        • U.O.C. di Oncologia Medica, A.O.R.N. "Antonio Cardarelli"
      • Orbassano, Italy, 10043
        • Oncologia Medica, A.O. Universitaria San Luigi Gonzaga
      • Piacenza, Italy, 29100
        • U.O. di Oncologia, AUSL di Piacenza
      • Pordenone, Italy, 33170
        • Unita Oncologica, Azienda Ospedaliera S. Maria degli Angeli
      • Siena, Italy, 53100
        • U.O.C. di Oncologia Medica, Policlinico "Le Scotte"
      • Verona, Italy, 37134
        • Oncologia Medica d.U., Policlinico G.B. Rossi, A.O.U.I. Verona
  • Spain
      • Barcelona, Spain, 08036
        • Hospital Clinic i Provincial de Barcelona
      • Barcelona, Spain, 08035
        • Medical Oncology, Hospital Vall d'Hebron
      • L'Hospitalet De Llobregat, Barcelona, Spain, 08907
        • Medical Oncology, Institut Català d'Oncologìa
      • Madrid, Spain, 28007
        • Oncología, Hospital Universitario Gregorio Marañón
      • Madrid, Spain, 28034
        • Servicio de Oncologìa Médica, Hospital Universitario Ramòn y Cajal
      • Madrid, Spain, 28040
        • Oncología Médica, Hospital Clínico San Carlos
      • Sabadell, Barcelona, Spain, 08208
        • Oncology, Corporaciò Sanitària Parc Taulì

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

Documented patient history

  • Histologically confirmed diagnosis of prostate cancer, with an available Gleason score.
  • Diagnosis of progressive, castration-resistant prostate cancer (CRPC), leading to inception of first-line chemotherapy with a docetaxel-based regimen.
  • Completion of chemotherapy with a cumulative delivered dose of 300 to 825 mg/m2 docetaxel.

Note: Pre-chemotherapy exposure to abiraterone and prednisone does not preclude eligibility, provided that both agents have been discontinued prior to initiation of docetaxel.

Current patient status

  • Ability to understand study-related patient information and provision of written informed consent for participation in the study.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least 6 months.
  • An interval ≥4 weeks elapsed from the last docetaxel administration.
  • Documented achievement of response or disease stability with docetaxel chemotherapy.
  • Absence of cancer-related symptoms suggesting clinical disease progression.
  • Current castrate testosterone level (≤50 ng/dL) due to current gonadotropin-releasing hormone (GnRH) agonist or antagonist therapy or past orchiectomy.
  • Haematology and blood chemistry tests within specified limits.
  • Successful recovery from acute toxicities from prior chemotherapy.
  • Confirmation from the immunology laboratory that the blood sample provided for baseline immunological tests is technically adequate.

Exclusion Criteria:

  • Known intolerance to Montanide or imiquimod.
  • Known presence of brain metastatic disease or spinal cord compression.
  • Radiotherapy within the past 4 weeks.
  • Concomitant presence of other primary malignancy
  • Major surgery within 4 weeks prior to randomisation.
  • Cardiovascular illness or complication which, in Investigator's judgment, compromises prognosis at 6 months or prevents the patient from following study procedures.
  • Serious uncontrolled infection.
  • Known presence of active autoimmune disease.
  • Known presence of acquired, hereditary, or congenital immunodeficiency.
  • HIV infection.
  • Current need for immunosuppressive drug therapy, including systemic corticosteroids.
  • Current need for denosumab therapy. (Patients under bisphosphonate treatment are eligible).
  • Skin disease interfering with evaluation of local tolerance of GX301 injections.
  • Participation in any interventional drug or medical device study within 30 days prior to treatment start.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: GX301 Regimen A (8 administrations)
Administration time frame: Day 1 to Day 63.
Biological: GX301

GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.

Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).

Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG.
Experimental: GX301 Regimen B (4 administrations)
Administration time frame: Day 1 to Day 63.
Biological: GX301

GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.

Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).

Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG.
Experimental: GX301 Regimen C (2 administrations)
Administration time frame: Day 1 to Day 63.
Biological: GX301

GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.

Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).

Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Achievement of immunological response
Time Frame: Days 90 and 180 following randomisation
Days 90 and 180 following randomisation
Incidence of adverse events
Time Frame: Up to Day 180
Up to Day 180
Changes from baseline in laboratory tests for immunological safety
Time Frame: Days 63, 90 and 180
Days 63, 90 and 180

Secondary Outcome Measures

Outcome Measure
Time Frame
Changes from baseline in serum prostate-specific antigen (PSA)
Time Frame: Up to Day 540 or end of observation (if earlier)
Up to Day 540 or end of observation (if earlier)
Progression-free survival
Time Frame: Up to Day 540 or end of observation (if earlier)
Up to Day 540 or end of observation (if earlier)
Overall survival
Time Frame: Up to Day 720
Up to Day 720
Incidence of adverse events
Time Frame: Up to Day 540 or end of observation (if earlier)
Up to Day 540 or end of observation (if earlier)
Changes from baseline in laboratory tests for immunological safety
Time Frame: Up to Day 540 or end of observation (if earlier)
Up to Day 540 or end of observation (if earlier)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Laboratoires Leurquin Mediolanum

Collaborators

Universita degli Studi di Genova

Investigators

  • Principal Investigator: Francesco Boccardo, MD, DIMI, Università di Genova - Clinica di Oncologia Medica, IRCCS San Martino-IST

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2014

Primary Completion (Actual)

August 1, 2018

Study Completion (Actual)

November 1, 2019

Study Registration Dates

First Submitted

November 14, 2014

First Submitted That Met QC Criteria

November 17, 2014

First Posted (Estimate)

November 18, 2014

Study Record Updates

Last Update Posted (Actual)

July 22, 2020

Last Update Submitted That Met QC Criteria

July 21, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MED-GX301-02
  • 2014-000095-26 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe